Top Medical News
Pearl Toh, 12 hours ago
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Stephen Padilla, 17 hours ago
Patients receiving chlorthalidone are less likely to develop treatment-resistant hypertension compared with those receiving amlodipine or lisinopril, according to a study that titrated medications to a goal. However, the risk of cardiovascular outcomes remains similar for patients with treatment-resistant hypertension across all three therapy groups.
18 hours ago
Patients with diabetic macula oedema (DME) slow down the development of proliferative diabetic retinopathy (PDR) and progression of DR with sustained intraocular delivery of fluocinolone acetonide (FAc), a recent study shows.
Yesterday
Use of valbenazine once daily has significantly improved tardive dyskinesia and is well tolerated in patients with underlying schizophrenia, schizoaffective disorder or mood disorder, according to the results of a phase III study.
Pearl Toh, 2 days ago
Treatment with inclisiran, a siRNA for PCSK9 knockdown, delivers significant and sustained LDL-C lowering in a dose-dependent manner over 6 to 9 months in patients with high cardiovascular (CV) risk, according to the ORION-1* study presented at the ACC.17 Scientific Session held in Washington, DC, US.
2 days ago
Paediatric rheumatology clinicians are largely inconsistent regarding when and how to withdraw medications for children with clinically inactive juvenile idiopathic arthritis (JIA), a recent study has found.
Roshini Claire Anthony, 3 days ago

Patients with atrial fibrillation (AF) given digoxin appear to have an elevated risk of mortality, regardless of whether or not they have heart failure, according to a post hoc analysis of the ARISTOTLE* trial presented at the American College of Cardiology (ACC) 66th Scientific Session in Washington DC, US. 

Special Reports
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
Roshini Claire Anthony, 24 Jan 2017

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
16 Dec 2016
ESMYA – Ulipristal acetate 5 mg tab – Zuellig Pharma
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Conference Reports
Pearl Toh, 27 Mar 2017
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Pearl Toh, 25 Mar 2017
Treatment with inclisiran, a siRNA for PCSK9 knockdown, delivers significant and sustained LDL-C lowering in a dose-dependent manner over 6 to 9 months in patients with high cardiovascular (CV) risk, according to the ORION-1* study presented at the ACC.17 Scientific Session held in Washington, DC, US.
Roshini Claire Anthony, 24 Mar 2017

Patients with atrial fibrillation (AF) given digoxin appear to have an elevated risk of mortality, regardless of whether or not they have heart failure, according to a post hoc analysis of the ARISTOTLE* trial presented at the American College of Cardiology (ACC) 66th Scientific Session in Washington DC, US. 

Audrey Abella, 24 Mar 2017
Anticoagulants (ie, novel oral anticoagulants [NOACs], warfarin) were effective in treating subclinical leaflet thrombosis after aortic valve replacement (AVR) compared with dual antiplatelet therapy (DAPT) or mono-antiplatelet therapy (MAPT), according to data presented at the American College of Cardiology’s (ACC) 66th Annual Scientific Session, held in Washington, DC, US.
Audrey Abella, 24 Mar 2017
Adding low-dose rivaroxaban to ticagrelor or clopidogrel did not result in major bleeding complications in patients with acute coronary syndrome (ACS) compared with patients on standard dual antiplatelet therapy (DAPT) of aspirin plus antiplatelet, according to the GEMINI-ACS-1* trial.
Roshini Claire Anthony, 21 Mar 2017

Prophylactic infusion of levosimendan did not reduce death or perioperative myocardial infarction or the need for dialysis or mechanical cardiac assist device more than placebo in patients at risk for low cardiac output syndrome undergoing cardiac bypass. However, it increased cardiac output and reduced low cardiac output syndrome, according to primary findings of the LEVO-CTS* trial. 

Pearl Toh, 21 Mar 2017
Intensive LDL lowering through the addition of the PCSK9* inhibitor evolocumab to statin therapy significantly reduced the risk of cardiovascular (CV) events in patients with existing atherosclerotic CV disease, according to data from the FOURIER** trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD